Literature DB >> 23160607

[Transforming growth factor β in prostate cancer: cellular effects and basic molecular mechanisms].

M B Stope1, C Rönnau, T Schubert, D Staar, J Bradl, P Ziegler, A Streitbörger, N Kroeger, U Zimmermann, R Walther, M Burchardt, C Börgermann.   

Abstract

The multifunctional cytokine transforming growth factor β (TGFβ) plays a dual role in prostate cancer (PCa), cell growth and tumorigenesis, reflected by its opposing properties of anti-oncogenic (e.g. growth inhibition and apoptosis) and pro-oncogenic effects (e.g. proliferation, cell motility and remodelling of the microenvironment). In the later stages of PCa, TGFβ loses anti-proliferative and thereby tumor-suppressive functions and shifts to a tumorigenic phenotype, mainly initiated by cross-talk between TGFβ signalling and other proliferation signal transduction pathways, such as mitogen-activated protein kinase (MAPK) and androgen receptor (AR) signalling. Although TGFβ plays an important role in tumor progression little is known about the underlying effects of TGFβ in the molecular pathology of PCa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23160607     DOI: 10.1007/s00120-012-3049-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  36 in total

Review 1.  Smad transcription factors.

Authors:  Joan Massagué; Joan Seoane; David Wotton
Journal:  Genes Dev       Date:  2005-12-01       Impact factor: 11.361

2.  Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate.

Authors:  K T Perry; C T Anthony; M S Steiner
Journal:  Prostate       Date:  1997-10-01       Impact factor: 4.104

3.  Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells.

Authors:  Matthias B Stope; Tina Schubert; Doreen Staar; Cindy Rönnau; Andreas Streitbörger; Nils Kroeger; Constanze Kubisch; Uwe Zimmermann; Reinhard Walther; Martin Burchardt
Journal:  World J Urol       Date:  2012-02-24       Impact factor: 4.226

4.  Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells.

Authors:  Beibei Zhu; Kei Fukada; Haining Zhu; Natasha Kyprianou
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.

Authors:  Jae-Il Park; Min-Goo Lee; Kyucheol Cho; Bum-Joon Park; Kwon-Seok Chae; Do-Sun Byun; Byung-Kyu Ryu; Yong-Keun Park; Sung-Gil Chi
Journal:  Oncogene       Date:  2003-07-10       Impact factor: 9.867

6.  Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components.

Authors:  C Festuccia; M Bologna; G L Gravina; F Guerra; A Angelucci; I Villanova; D Millimaggi; A Teti
Journal:  Int J Cancer       Date:  1999-05-05       Impact factor: 7.396

7.  Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines.

Authors:  I Sehgal; T C Thompson
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

Review 8.  More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.

Authors:  Seun Ajiboye; Tristan M Sissung; Nima Sharifi; William D Figg
Journal:  BJU Int       Date:  2010-01-08       Impact factor: 5.588

9.  Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.

Authors:  F Yang; D W Strand; D R Rowley
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

10.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

View more
  1 in total

Review 1.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.